Cell & Gene Meeting on the Mesa 2022 Recap
November 9, 2022 -- The Science and Medicine Group team was onsite at this year's Cell & Gene Meeting on the Mesa getting the who, what, and when on the product announcements, science sessions, and deals taking place this year. Find out what we learned in our recap. Read More
Gene therapy targets overactive brain cells in mice, potential neurological treatment
November 4, 2022 -- University College London researchers have developed a gene therapy for neurological and psychiatric diseases that reduces the excitability of overactive brain cells. Tested in mice, the scientists contend the treatment could potentially be used in human brain diseases caused by excessive activity of a small number of brain cells. Read More
Academic CDMOs, like commercial ones, play critical role in CGT sector
October 27, 2022 -- The cell and gene therapy (CGT) industry is growing and academic contract development and manufacturing organizations (CDMOs) -- like their larger commercial counterparts -- are playing a critical role in the ecosystem, according to Stuart Curbishley, PhD, head of business and process development at the University of Birmingham’s Advanced Therapies Facility. Read More
Induced pluripotent stem cell technology offers potential treatment for hair loss
October 25, 2022 -- Science Advisory Board spoke with Stemson Therapeutics co-founder and CEO Geoff Hamilton earlier this month at the 2022 Cell & Gene Meeting on the Mesa about the preclinical stage cell therapy company's focus on curing hair loss by leveraging the regenerative power of induced pluripotent stem cells. Read More
Researchers slash time needed to produce CAR T cells for cancer patients in need
October 25, 2022 -- Researchers at University Hospitals Seidman Cancer Center and their collaborators have streamlined the production of CAR T cells, a mainstay of modern immunotherapy treatment for certain cancers. Read More
Cell therapy startup NKILT Therapeutics takes novel approach to targeting leukemia
October 24, 2022 -- Biotech startup NKILT Therapeutics is developing a novel approach of engineering natural killer cells to directly target leukemias and solid tumors. Science Advisory Board spoke with Raphaël Ognar, co-founder and CEO of the company earlier this month at the 2022 Cell & Gene Meeting on the Mesa in Carlsbad, CA. Read More
Antion Biosciences takes allogeneic approach to therapies with microRNA technology
October 21, 2022 -- Science Advisory Board spoke with Dr. Sven Kili, CEO of Antion Biosciences, at last week’s 2022 Cell & Gene Meeting on the Mesa, where he laid out his vision for where the company is heading and what the industry needs to do to cure diseases with significant unmet medical needs. Read More
CDMO Lonza continues drive to support cell and gene therapy commercial customers
October 20, 2022 -- In an interview with Science Advisory Board, Alberto Santagostino, senior vice president and head of cell and gene technologies at Swiss contract development and manufacturing organization (CDMO) Lonza, discussed bluebird bio's two recent U.S. Food and Drug Administration-approved gene therapies. Read More
Low phosphate levels linked with CAR T neurological toxicity
October 20, 2022 -- Patients with hypophosphatemia had higher incidences and more severe neurological side effects on chimeric antigen receptor (CAR) T-cell therapy than those with normal blood phosphate levels, according to a study published October 19 in the journal Cancer Immunology Research. Read More
Cell and gene therapy sector is in midst of an ‘industrial revolution’: Miguel Forte
October 18, 2022 -- Science Advisory Board spoke with Dr. Miguel Forte, CEO of Bone Therapeutics and president-elect of the International Society for Cell & Gene Therapy, at last week’s 2022 Cell & Gene Meeting on the Mesa about the state of the cell and gene therapy sector. Read More
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter